Mundipharma Research GmbH & Co KG clinical trials

A subsidiary of Mundipharma

The registry lists 16 studies whose lead sponsor is Mundipharma Research GmbH & Co KG. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2018.

Studies

Recruiting first, then most recently updated. Showing 16 of 16. All Mundipharma studies →

• Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime SymptomsCompletedNCT01112644Phase 3

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer TherapyCompletedNCT01438567Phase 3

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related ConstipationCompletedNCT00412100Phase 3

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• Oxycodone-naloxone in Relieving Opioid-related ConstipationCompletedNCT00412152Phase 3

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer PainCompletedNCT00513656Phase 2

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant PainCompletedNCT01971632Phase 3

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)CompletedNCT01197261Phase 2

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA SubjectsCompletedNCT00902837Phase 3

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2.CompletedNCT03062644Phase 3

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• Efficacy and Safety in a Randomised Acute Pain Study of MR308 (Tramadol/Celecoxib).CompletedNCT02982161Phase 3

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer PainCompletedNCT02321397Phase 2/3

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC).CompletedNCT01957046Phase 4

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• A Study to Explore the Influence of Two Opioid Pain Medications on Bacterial Composition in the Gut and Other Gastrointestinal AspectsCompletedNCT01915147Phase 2

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated PainCompletedNCT01439100Phase 3

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic PolyneuropathyCompletedNCT00944697Phase 2

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG

• Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of PainCompletedNCT00992576Phase 2/3

  Sponsor listed in the registry: Mundipharma Research GmbH & Co KG